PMID- 37650759
OWN - NLM
STAT- MEDLINE
DCOM- 20231116
LR  - 20231207
IS  - 1473-5571 (Electronic)
IS  - 0269-9370 (Print)
IS  - 0269-9370 (Linking)
VI  - 37
IP  - 15
DP  - 2023 Dec 1
TI  - Immunogenicity and reactogenicity of yellow fever vaccine in people with HIV.
PG  - 2319-2329
LID - 10.1097/QAD.0000000000003696 [doi]
AB  - OBJECTIVE: To evaluate immunogenicity and reactogenicity of yellow fever (YF) 
      vaccine in people with HIV (PWH) compared to HIV-uninfected controls. DESIGN: In 
      this longitudinal interventional trial (NCT03132311), PWH with CD4 + cell count 
      >/=200 cells/mul and controls, aged 18-59, without a previous history of YF 
      vaccination received a single standard dose of YF vaccine (17DD) and were 
      followed at Days 5, 30 and Year 1. METHODS: YF-neutralization titers were 
      measured at Days 0, 30 and Year 1 and geometric mean titers (GMT) were 
      calculated. Adverse events (AE) and YF virus detection were measured at Days 5 
      and 30. Linear regression evaluated factors associated with YF-neutralization 
      titers. RESULTS: Two hundred and eighteen PWH and 82 controls were included. At 
      baseline, all PWH were using antiretroviral therapy; 92.6% had undetectable HIV 
      viral load (VL) and median CD4 + cell count was 630 cells/mul [interquartile range 
      (IQR) 463-888]. YF vaccine was safe and there were no serious AEs. At Day 30, 
      seroconversion was observed in 98.6% of PWH [95% confidence interval (CI): 
      95.6-99.6] and in 100% of controls (95% CI: 93.9-100); at Year 1, 94.0% of PWH 
      (95% CI: 89.6-96.7) and 98.4% of controls (95% CI 90.3-99.9) were seropositive. 
      PWH had lower GMTs than controls at Day 30 and Year 1. Baseline VL 
      >1000 copies/ml, low CD4 + cell count and low CD4 + /CD8 + ratio were associated 
      with lower YF-neutralization titers. CONCLUSIONS: YF vaccine is safe in PWH with 
      CD4 + cell count >/=200 cells/mul. YF vaccine immunogenicity is impaired in PWH, 
      particularly among those with high VL, low CD4 + cell count and low CD4 + /CD8 + 
      ratio at vaccination and YF-neutralization titers decays over time.
CI  - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Motta, Edwiges
AU  - Motta E
AD  - Instituto Nacional de Infectologia Evandro Chagas - Fundacao Oswaldo Cruz.
FAU - Camacho, Luiz Antonio B
AU  - Camacho LAB
AD  - Escola Nacional de Saude Publica Sergio Arouca - Fundacao Oswaldo Cruz.
FAU - Cunha, Marcelo
AU  - Cunha M
AD  - Escola Nacional de Saude Publica Sergio Arouca - Fundacao Oswaldo Cruz.
FAU - de Filippis, Ana Maria Bispo
AU  - de Filippis AMB
AD  - Laboratorio de Flavivirus, Instituto Oswaldo Cruz - Fundacao Oswaldo Cruz.
FAU - Lima, Sheila M B
AU  - Lima SMB
AD  - Departamento de Desenvolvimento Experimental e pre-Clinico (DEDEP), 
      Bio-Manguinhos/Fiocruz.
FAU - Costa, Marcellus
AU  - Costa M
AD  - Instituto Nacional de Infectologia Evandro Chagas - Fundacao Oswaldo Cruz.
FAU - Pedro, Luciana
AU  - Pedro L
AD  - Instituto Nacional de Infectologia Evandro Chagas - Fundacao Oswaldo Cruz.
FAU - Cardoso, Sandra W
AU  - Cardoso SW
AD  - Instituto Nacional de Infectologia Evandro Chagas - Fundacao Oswaldo Cruz.
FAU - Cortes, Fernanda Heloise
AU  - Cortes FH
AD  - Laboratorio de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz - Fundacao 
      Oswaldo Cruz.
FAU - Giacoia-Gripp, Carmem B W
AU  - Giacoia-Gripp CBW
AD  - Laboratorio de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz - Fundacao 
      Oswaldo Cruz.
FAU - Morata, Michelle
AU  - Morata M
AD  - Instituto Nacional de Infectologia Evandro Chagas - Fundacao Oswaldo Cruz.
FAU - Nazer, Sandro
AU  - Nazer S
AD  - Instituto Nacional de Infectologia Evandro Chagas - Fundacao Oswaldo Cruz.
FAU - Moreira, Ronaldo Ismerio
AU  - Moreira RI
AD  - Instituto Nacional de Infectologia Evandro Chagas - Fundacao Oswaldo Cruz.
AD  - Escola Nacional de Saude Publica Sergio Arouca - Fundacao Oswaldo Cruz.
FAU - de Oliveira Souza, Marta Cristina
AU  - de Oliveira Souza MC
AD  - Laboratorio de Tecnologia Virologica (LATEV), Bio-Manguinhos/Fiocruz.
FAU - Mendes, Ygara S
AU  - Mendes YS
AD  - Laboratorio de Tecnologia Virologica (LATEV), Bio-Manguinhos/Fiocruz.
FAU - Souza Azevedo, Adriana de
AU  - Souza Azevedo A
AD  - Laboratorio de Analise Imunomolecular (LANIM), Bio-Manguinhos/Fiocruz, Rio de 
      Janeiro, Brazil.
FAU - Dos Santos Alvez, Nathalia
AU  - Dos Santos Alvez N
AD  - Laboratorio de Analise Imunomolecular (LANIM), Bio-Manguinhos/Fiocruz, Rio de 
      Janeiro, Brazil.
FAU - Grinsztejn, Beatriz
AU  - Grinsztejn B
AD  - Instituto Nacional de Infectologia Evandro Chagas - Fundacao Oswaldo Cruz.
FAU - Coelho, Lara E
AU  - Coelho LE
AD  - Instituto Nacional de Infectologia Evandro Chagas - Fundacao Oswaldo Cruz.
LA  - eng
SI  - ClinicalTrials.gov/NCT03132311
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230823
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
RN  - 0 (Yellow Fever Vaccine)
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Antibodies, Viral)
SB  - IM
MH  - Humans
MH  - *Yellow Fever Vaccine
MH  - *Yellow Fever/prevention & control
MH  - Antibodies, Neutralizing
MH  - *HIV Infections/complications
MH  - Vaccination/adverse effects
MH  - Antibodies, Viral
PMC - PMC10653289
COIS- There are no conflicts of interest.
EDAT- 2023/08/31 12:43
MHDA- 2023/11/16 06:44
PMCR- 2023/11/16
CRDT- 2023/08/31 10:13
PHST- 2023/11/16 06:44 [medline]
PHST- 2023/08/31 12:43 [pubmed]
PHST- 2023/08/31 10:13 [entrez]
PHST- 2023/11/16 00:00 [pmc-release]
AID - 00002030-990000000-00329 [pii]
AID - AIDS-D-23-00385 [pii]
AID - 10.1097/QAD.0000000000003696 [doi]
PST - ppublish
SO  - AIDS. 2023 Dec 1;37(15):2319-2329. doi: 10.1097/QAD.0000000000003696. Epub 2023 
      Aug 23.